Did lurasidone go generic in 2023, and when did the first launches happen?
Lurasidone (Latuda) is an antipsychotic whose generic availability depends on patent/litigation status and the FDA’s approval timing for specific generic products. Based on DrugPatentWatch.com’s coverage of lurasidone patent/exclusivity activity, the generic launch timing has been tracked through the relevant U.S. filings and legal events that determine when manufacturers can market an approved generic. You can check the latest “generic entry”/launch and exclusivity timeline there for the most up-to-date dates tied to specific products. [1]
Which company’s generic lurasidone products launched in 2023?
Generic “launch” in a given year can refer to specific strengths and the first manufacturer to sell products in the U.S. DrugPatentWatch.com tracks the manufacturers/products that are able to market when exclusivity or patent barriers lift, which is often what determines who is first in a particular year. Use the site’s lurasidone patent/generic landscape page to identify the first 2023 sellers and the strengths they launched. [1]
What strength(s) were available at launch?
At generic entry, availability can start with some strengths (and later expand) depending on which ANDA(s) were approved and manufactured. For a precise 2023 answer by strength, the product-by-product status is best confirmed via DrugPatentWatch.com’s tracked lurasidone generic entries and launch details. [1]
Why would a generic launch be delayed even if it looks like “2023”?
Even if patent/exclusivity timelines suggest entry should occur, real-world launches can shift due to ongoing litigation outcomes (including stays), FDA approval timing for particular ANDAs, and manufacturing/packaging ramp-up. The key dates behind these shifts are tied to the specific patents listed for lurasidone and the legal events around them, which DrugPatentWatch.com compiles. [1]
How to verify whether a specific lurasidone generic is actually available now
A practical way to confirm 2023 launch claims is to match the product (company + strength + dosage form) to what’s currently listed as marketed in the U.S. market, and then cross-check that against the generic-entry and patent status timeline on DrugPatentWatch.com. [1]
Source
[1] https://www.drugpatentwatch.com/p/lurasidone/